Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History TBPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics TBPH

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Theravance Biopharma Inc

TBPH
Current price
11.59 USD +0.33 USD (+2.93%)
Last closed 11.22 USD
ISIN KYG8807B1068
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 557 514 496 USD
Yield for 12 month +31.41 %
1Y
3Y
5Y
10Y
15Y
TBPH
21.11.2021 - 28.11.2021

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

17.20 USD

P/E Ratio

Dividend Yield

Financials TBPH

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures TBPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+64 381 000 USD

Last Year

+57 424 000 USD

Current Quarter

+15 388 000 USD

Last Quarter

+18 754 000 USD

Current Year

+64 381 000 USD

Last Year

+57 424 000 USD

Current Quarter

+15 388 000 USD

Last Quarter

+18 754 000 USD
EBITDA -43 972 000 USD
Operating Margin TTM -93.80 %
Price to Earnings
Return On Assets TTM -7.98 %
PEG Ratio -0.050
Return On Equity TTM -31.46 %
Wall Street Target Price 17.20 USD
Revenue TTM 65 266 000 USD
Book Value 3.32 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 6.10 %
Dividend Yield
Gross Profit TTM 28 018 000 USD
Earnings per share -1.18 USD
Diluted Eps TTM -1.18 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -89.38 %

Stock Valuation TBPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 555.56
Enterprise Value Revenue 7.28
Price Sales TTM 8.54
Enterprise Value EBITDA -9.69
Price Book MRQ 3.36

Technical Indicators TBPH

For 52 Weeks

7.44 USD 11.82 USD
50 Day MA 10.11 USD
Shares Short Prior Month 3 790 310
200 Day MA 9.33 USD
Short Ratio 11.72
Shares Short 3 977 181
Short Percent 12.88 %